Drugs / PF-4136309
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02598206 | Dec 2015 → May 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01413022 | Apr 2012 → Oct 2013 | pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02732938 | May 2016 → Sep 2017 | pancreatic ductal adenocarcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00689273 | Aug → Nov 2008 | osteoarthritis, knee | Pfizer | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01226797 Comparator | Jan 2011 → Feb 2012 | chronic hepatitis C virus infection | Pfizer | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-4136309 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2029422 ↗ |
| Known as | INCB-8761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2029422 ↗ |
| Known as | PF-04136309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02598206 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 2 antagonist” CHEMBL2029422 ↗1“CCR2 inhibitor PF-04136309” PMID 31297636 ↗ Jul 2019 |
| Modality | Small molecule | — CHEMBL2029422 ↗ |
| Route | Oral | “Take 4 capsules twice daily 12 hours apart with water. Swallow whole.” NCT01226797 ↗ |
| Target | CCR2 | “C-C chemokine receptor type 2 antagonist” CHEMBL2029422 ↗ |